Abstract 2052: TRIP13 amplification confers PARP inhibitor resistance and polymerase theta inhibitor sensitivity

Author(s):  
Jeffrey Patterson-Fortin ◽  
Jia Zhou ◽  
Alan D'Andrea
Cell Reports ◽  
2018 ◽  
Vol 23 (3) ◽  
pp. 918-929 ◽  
Author(s):  
Hsien-Ming Hu ◽  
Xin Zhao ◽  
Swati Kaushik ◽  
Lilliane Robillard ◽  
Antoine Barthelet ◽  
...  

BMC Cancer ◽  
2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Ruoxi Hong ◽  
Fei Ma ◽  
Weimin Zhang ◽  
Xiying Yu ◽  
Qing Li ◽  
...  

Author(s):  
Kasper Fugger ◽  
Graeme Hewitt ◽  
Stephen C. West ◽  
Simon J. Boulton

Cancers ◽  
2020 ◽  
Vol 12 (8) ◽  
pp. 2054
Author(s):  
Elizabeth K. Lee ◽  
Ursula A. Matulonis

The use of PARP inhibitors (PARPi) is growing widely as FDA approvals have shifted its use from the recurrence setting to the frontline setting. In parallel, the population developing PARPi resistance is increasing. Here we review the role of PARP, DNA damage repair, and synthetic lethality. We discuss mechanisms of resistance to PARP inhibition and how this informs on novel combinations to re-sensitize cancer cells to PARPi.


2019 ◽  
Vol 29 (10) ◽  
pp. 820-834 ◽  
Author(s):  
Sylvie M. Noordermeer ◽  
Haico van Attikum

2019 ◽  
Vol 19 (2) ◽  
pp. 602-613 ◽  
Author(s):  
Pyoung Hwa Park ◽  
Tomomi M. Yamamoto ◽  
Hua Li ◽  
Allen L. Alcivar ◽  
Bing Xia ◽  
...  

2019 ◽  
Author(s):  
Mark J. O'Connor ◽  
Cristina Cruz ◽  
Marta Castroviejo-Bermejo ◽  
Urszula M. Polanska ◽  
Gemma N. Jones ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document